Astaxanthin Supplementation in Cyclists

Athletic Performance Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01241877
• Other study ID #: MEC 10-3-068
• Status: Recruiting
• Phase: N/A
• First received: November 15, 2010
• Last updated: April 19, 2011
• Start date: November 2010

Study information

• Verified date: April 2011
• Source: Maastricht University Medical Center
• Contact: Peter Res, MSc
• Phone: +3143381383
• Email: peter.res[@]maastrichtuniversity.nl
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Background of the study:

Astaxanthin has been shown to be a powerfull anti-oxidant. Health benefits have been shown in animals and humans. Exercise enhancing effects have been shown in animals via enhancement of fat oxidation. We want to examine the effects of 4 weeks of astaxanthin supplementation on fat oxidation and cycling performance in trained cyclists

Objective of the study:

To test the hypothesis that 4 weeks supplementation with astaxanthin will improve fat oxidation and improve exercise performance in trained cyclists

Study design:

Double blind, placebo controlled study.

Study population:

Well trained cyclists between 18-30 years old

Intervention (if applicable):

astaxanthin (20 mg/day) or placebo for 4 weeks

Primary study parameters/outcome of the study:

performance on a time trial after 90 min steady state exercise.

Secundary study parameters/outcome of the study (if applicable):

substrate use plasma glucose plasma lactate plasma free fatty acid plasma astaxanthin

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):

The risks involved in participating in this experiment are minimal. Astaxanthin has been shown to be safe. Insertion of the catheters in a vein is comparable to a normal blood draw and the only risk is of a small local haematoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. primary completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy

• Male

• Age between 18 and 30 years

• Endurance trained (=3 sessions of endurance exercise per week)

• VO2 max = 50 ml/kg/min

• Training history of more than one year of =3 sessions of endurance exercise per week

• BMI <25 kg/m2

Exclusion Criteria:

• Use of medication

• Smoking

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Athletic Performance

Intervention

Dietary Supplement:
• astaxanthin
astaxanthin
• placebo
placebo

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht	LI

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time trial performance	time trial performance	4 weeks	No
Secondary	substrate use		4 weeks	No